
Concr
Techbio company that uses established methods from astrophysics to accurately predict patient outcomes and treatment response to novel and existing cancer therapies.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
* | N/A | Grant | |
Total Funding | 000k |
Related Content
ConcR is a pioneering company in the field of oncology, leveraging advanced software to identify complex predictive biomarkers from multi-omic data. This technology is instrumental in guiding clinical trial cohort selection, optimizing combination therapy strategies, and enhancing the market access potential of novel therapeutic candidates. By applying their solutions in the pre-clinical and clinical translation phases, ConcR aims to shorten R&D timelines and predict the sensitivity of cell lines to new drugs. The company serves both clinicians and pharmaceutical companies, providing decision support tools specifically for the treatment of pancreatic ductal adenocarcinoma and triple-negative breast cancer. ConcR's holistic approach, which integrates multiple data sources and methodologies, sets it apart in terms of accuracy and specificity. The company's mission is to reduce the uncertainty in treating cancer and developing new cancer therapeutics, with plans to expand into other indications such as colorectal, prostate, and ovarian cancers.
Keywords: oncology, biomarkers, clinical trials, cancer therapy, multi-omic data, R&D, decision support, pancreatic cancer, breast cancer, pharmaceutical.